PUBLISHER: Grand View Research | PRODUCT CODE: 1985974
PUBLISHER: Grand View Research | PRODUCT CODE: 1985974
The U.S. breast biopsy devices market size was estimated at USD 1.18 billion in 2025 and is anticipated to reach USD 1.60 billion by 2033, growing at a CAGR of 3.9% from 2026 to 2033. The market growth driven by the rising incidence of breast cancer and the consequent emphasis on early detection and accurate diagnosis, which increases the volume of biopsy procedures required in screening and diagnostic pathways.
High awareness among patients and clinicians, supported by structured screening programs and favorable reimbursement landscapes, further propels device adoption. In addition, technological advancements, including minimally invasive core-needle and vacuum-assisted systems, integration with advanced imaging modalities (e.g., ultrasound, MRI, 3D mammography), and AI-enhanced diagnostic workflows, are expanding clinical utility, improving procedural accuracy and patient comfort, and encouraging broader clinical integration.
The rising prevalence of breast cancer in the U.S. directly drives growth in the breast biopsy devices market because a higher number of new and suspected cancer cases increases the demand for diagnostic confirmation through tissue sampling. In the U.S., breast cancer is the most commonly diagnosed cancer among women, with hundreds of thousands of new invasive and non-invasive cases reported annually, prompting more routine screening and follow-up biopsies when abnormalities are detected on imaging. As incidence rates climb and screening programs expand, healthcare providers perform more biopsies to confirm diagnoses, guide treatment decisions, and rule out malignancy, thereby boosting utilization of core-needle, vacuum-assisted, and image-guided breast biopsy devices.
As screening programs such as mammography and MRI expand, more suspicious lesions are detected, necessitating tissue sampling via core-needle or vacuum-assisted biopsy. This sustained rise in diagnostic volumes increases demand for advanced, image-guided biopsy systems in hospitals and ambulatory centers. The link between higher case detection and device innovation is evident in recent industry developments, for instance, in February 2026, Mammotome, a part of Danaher Corporation, introduced the Mammotome Prima MR Dual Vacuum-Assisted Breast Biopsy System, the first system designed to be positioned inside the MRI scanner room at the patient's side during biopsy. By improving clinician coordination and workflow efficiency in MRI-guided procedures, such innovations address the growing procedural burden driven by rising breast cancer prevalence, thereby accelerating technology adoption and overall market growth in the U.S. breast biopsy devices sector.
U.S. Breast Biopsy Devices Market Report Segmentation
This report forecasts revenue growth at the country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the U.S. breast biopsy devices market report based on product, procedure type, guidance technology, and end use: